CSP
DNTH icon

Cary Street Partners’s Dianthus Therapeutics DNTH Stock Holding History

Cary Street Partners’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$355K Buy
+3,645
New +$318K 0.01% 756

Other funds holding DNTH

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
MAP
Moody Aldrich Partners Marblehead, Massachusetts $557M AUM 122.79% 1-Year Est. Return
PFA
Peak Financial Advisors Denver, Colorado $242M AUM 19.63% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
PR
PSP Research Newtown Square, Pennsylvania $188M AUM
LI
LRI Investments Palm Beach Gardens, Florida $1.24B AUM 11.13% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.69B AUM 42.78% 1-Year Est. Return
GBT
Grove Bank & Trust Miami, Florida $1.01B AUM 26.88% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.53B AUM 30.05% 1-Year Est. Return

Cary Street Partners's DNTH Position: Q2 2026 in Review

Cary Street Partners opened a new position in Dianthus Therapeutics (DNTH) in Q2 2026: 3,645 shares worth $355K. The stake represents 0.01% of the portfolio and ranks #756 among its holdings.

12 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • Cary Street Partners held 3,645 shares of Dianthus Therapeutics worth $355K as of Q2 2026.
  • Dianthus Therapeutics was a new Cary Street Partners position in Q2 2026.
  • Dianthus Therapeutics made up 0.01% of Cary Street Partners's portfolio in Q2 2026, its #756 holding.
  • 12 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on Cary Street Partners's 13F filing for Q2 2026, filed 17 Jul 2026.